Drug interactions with psychostimulants

International Clinical Psychopharmacology

Volumn 14, Issue 1, 1999, Pages 1-18

  Markowitz, J S ^a   Morrison, S D ^a   Lindsay DeVane, C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dextroamphetamine; Drug interactions; Methylphenidate; Pemoline; Psychostimulant

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; PEMOLINE; PSYCHOSTIMULANT AGENT;

ARTICLE; DRUG INFORMATION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEXTROAMPHETAMINE; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; METHYLPHENIDATE; PEMOLINE;

EID: 0032957511     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199901000-00001     Document Type: Article

References (92)

1. Bahatar VS, Kallepaull BR, Misra LK, Awadallah S (1996) A possible clonidine-trazodone-dextroamphetamine interaction in a 12-year-old boy. J Child Adolescent Psychopharmacol 6:203-209.
2. Beckett AH, Rowland M (1965) Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol 17:628-639.
3. Beckett AH, Rowland M, Turner P (1965) Influence of urinary pH on excretion of amphetamine. Lancet 1:303.
4. Bellward G, Read, III JM, Garrettson LK (1969) Further studies of the inhibition of drug metabolism by methylphenidate [abstract]. Fed Proc 28:418.
5. 6] ethanol: preliminary in vitro findings using a rat liver preparation. J Pharmaceut Sci 86:1494-1496.
6. Brzezinski MR, Abraham TL, Stone CL, Dean RA, Bosron WF (1994) Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 48:1747-1755.
7. Burke MS, Josephson A, Lightsey A (1995) Combined methylphenidate and imipramine complication. J Am Acad Child Adolescent Psychiatry 34:403-404.
8. Cantwell DP (1996) Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolescent Psychiatry 35:978-987.
9. Connor DF, Benjamin S, Ozbayrak KR (1995) Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment. J Am Acad Child Adolescent Psychiatry 34:1490-1494.
10. Connor DF, Ozbayrak KR, Kusiak K, Caponi AB, Melloni RH (1997) Combined pharmacotherapy in children and adolescents in a residential treatment center. J Am Acad Child Adolescent Psychiatry 36:248-254.
11. Connors CK, Taylor E (1980) Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry 37:922-930.
12. Connors CK, Taylor E, Meo G, Kurtz MA, Fournier M (1972) Magnesium pemoline and dextroamphetamine: a controlled study in children with minimal brain dysfunction. Psychopharmacologia 26:321-336.
13. Cooper TB, Simpson GM (1973) Concomitant imipramine and methylphenidate administration: a case report [let-ter]. Am J Psychiatry 130:72.
14. Cylert Product Information (1998) Abbott Park, IL: Abbott Laboratories.
15. Dally PJ (1962) Fatal reaction associated with tranylcypromine and methylamphetamine [letter]. Lancet 1:1235-1236.
16. Davis JM, Kopin IJ, Lemberger L, Axelrod J (1971) Effects of urinary pH on amphetamine metabolism. Ann NY Acad Sci 179:493.
17. Day MD (1962) Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium and xylocholine. Br J Pharmacol 18:421-439.
18. Dayton PG, Johnson LD, Wilson CH, Perel JM (1969) Inhibition of the metabolism of phenylbutazone by methylphenidate in man. Pharmacologist 11:272.
19. De Vane CL, Sallec FR (1996) Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 57:55-66.
20. Drimmer EJ, Gitlin MJ, Gwirtsman HE (1983) Desipramine and methylphenidate combination treatment for depression: case report. Am J Psychiatry 140:241-242.
21. Dulcan M, and the Work Group on Quality Issues (1997) J Am Acad Child Adolescent Psychiatry 36 (Suppl): 85S-121S.
22. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR (1991) CNS stimulant potentiation of monoamine oxidase inhibitors in the treatment of depression. J Clin Psychopharmacol 11:127-132.
23. Feeney DJ, Klykylo WM (1997) Meditation-induced seizures [letter]. J Am Acad Child Adolescent Psychiatry 36:1018-1019.
24. Feighner JP, Herbstein J, Damlouji N (1985) Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 46:206-209.
25. Fenichel RR (1995) Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolescent Psycopharmacol 5:155-156.
26. Kindling RI (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of scrotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolescent Psychopharmacol 16:165-175.
27. Flegin OT, Morgan DH, Oates JA, Shand DU (1970) The mechanism of the reversal of the effect of guanethidine by amphetamines in cat and man. Br J Pharmacol 39:253P-254P
28. Flemenbaum A (1972) Hypertensive episodes after adding methylphenidate (Ritalin) to tricyclic antidepressants. Psychosomatics 13:265-268.
29. Gammon GD, Brown TE (1993) Fluoxetine and methylphenidate combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolescent Psychopharmacol 3:1-10.
30. Garrettson LK, Perel JM, Dayton PC (1969) Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. J Am Med Assoc 207:2053-2056.
31. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding Y-S (1996) Affinities of methylphenidate derivitives for dopamine, norepinephrine and scrotonin transporters. Life Sci 58:231-239.
32. Gerkens JF, McCulloch MW, Wilson J (1969) Mechanism of the antagonism between guanethidine and dexamphetamine. Br J Pharmacol 35:563-572.
33. Ghofrani M (1988) Possible phenytoin-methylphenidate interaction. Dev Med Child Neurol 30:266-268.
34. Gibaldi M, Grundhofer B, Levy G (1975) Time course and dose dependence of antacid effect on urine pH. J Pharmaceut Sci 64:2003-2004.
35. Gittleman-Klein R, Klein DF, Katz S, Saraf K, Pollack E (1976) Comparative effects of methylphenidate and thioridazine in hyperkinetic children. Arch Gen Psychiatry 33:1217-1231.
36. Gokhale SD, Gulati OD, Udwadia BP (1966) Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs. Arch Int De Pharmacodyn Therap 160:321-329.
37. Grob CS, Coyle JT (1986) Suspected adverse methylphenidate-imipramine interactions in children. J Dev Behav Pediatr 7:265-267.
38. Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev RS (1997) Epilepsy and attention defecit disorder: is methylphenidate safe and effective? J Pediatrics 130:40-44.
39. Gulati OD, Dave BT, Gokhale SD, Shah KM (1966) Antagonism of adrenergic neuron blockade in hypertensive subjects. Clin Pharmacol Therapeut 7:510-514.
40. Gupta S, Ghaly N, Dewan M (1992) Augmenting fluoxetine with dextroamphetamine to treat refractory depression [letter]. Hosp Commun Psychiatry 43:281-283.
41. Gwirtsman HE, Szuba MO, Toren L, Feist M (1994) The antidepressant response to tricyclics is accelerated with the adjunctive use of methylphenidate. Psychopharmacol Bull 30:157-164.
42. Hague DE, Smith ME, Ryan JR, McMahon FG (1971) The effect of methylphenidate and prolintane on the metabolism of ethylbiscoumacetate. Clin Pharmacol Therapeut 12:259-262.
43. Hunningshake D (1970) Studies of the inhibition of drug metabolism by methytphenidate [abstract]. Fed Proc 29:345.
44. Hunt RD, Cohen DJ, Anderson G, Clark L (1984) Possible changes in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine in children with attention deficit disorder with hyperactivity. Life Sci 35:885-897.
45. Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levoamphetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304-308.
46. Kaplan SL, Simms RM, Busner J (1994) Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolescent Psychiatry 1:35-44.
47. Kirsko I, Lewis E, Johnson JE (1969) Severe hyperexia due to tranylcypromine-amphetamine toxicily. Ann Intern Med 70:559-564.
48. Kotaki H, Aoyama T, Nakazato F, Saitoh Y, Nakagawa F (1988) Interactions in tissue distribution between methylphenidate and pemoline, H. Effects of methylphenidate or its metabolite on plasma and tissue concentrations of pemoline in rat. Chem Pharmaceut Bull 36:4560-4566.
49. Kupferberg HJ, Jeffery W, Huninghake DB (1972) Effect of methylphenidate on plasma anticonvulsant levels. Clin Pharmacol Therapeut 13:201-204.
50. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP et al. (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827-832.
51. Levy F, Hobbes G (1988) The action of stimulant medication in attention deficit disorder with hyperactivity: dopaminergic, noradrenergic, or both? J Am Acad Child Adolescent Psychiatry 27:802-805.
52. Levy F, Hobbes G (1996) Does haloperidol block methylphenidate? Motivation or attention? Psychopharmacology 126:70-74.
53. Linet LS (1989) Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine [letter]. Am J Psychiatry 146:803-804.
54. Lloyd JTA, Walker DRH (1965) Death after combined dextroamphetamine and phenelzine [letter]. BMJ 2:168-169.
55. Markowitz J, Patrick K (1996) Polypharmacy side effects [letter]. J Am Acad Child Adolescent Psychiatry 35:842.
56. Markowilz JS, Wells BG, Carson WH (1995) Interactions between antipsychotic and antihypertensive agents. Ann Pharmacother 29:603-609.
57. Mason A (1962) Fatal reaction associated wilh tranylcypromine and methylamphetamine [letter]. Lancet 1:1073.
58. McArdle P, O'Brien G, Kolvin I (1995) Hyperactivity: presence and relationship with conduct disorder. J Child Psychol Psychiatry 36:279-303.
59. McGlohn SE, Bostwick JM (1995) Sertraline with methylphenidate. in an ICU patient [letter]. Psychosomatics 36:584-585.
60. Metz A, Shader R (1991) Combination of fluoxetine with pemoline in the treatment of major depressive disorder. Int J Clin Psychopharmacol 6:93-96.
61. Mirkin BL, Wright F (1971) Drug interaction: effects of methylphenidate on the disposition of diphenylhydantoin in man. Neurology 21:1123-1128.
62. Nemeroff CB, DeVane CL, Pollock BG (1996) Antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
63. O'Reilly RA, Trager WF, Motley CH (1980) Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest 65:746-753.
64. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM (1993) Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolescent Psychiatry 32:1065-1072.
65. Patrick KS, Markowitz JS (1997) Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder: a review. Hum Psychopharmacol 12:527-546.
66. Patrick KS, Mueller RA, Gualtieri CT, Breese GR (1987) Pharmacokinetics and actions of methylphenidate. In: Psychopharmacology: The Third Generation of Progress (HY Meltzer, ed.), New York, NY: Raven Press, pp. 1387-1395.
67. Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM et al. (1990) Relative efficay of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226-237.
68. Perel JM, Black N, Wharton RN, Malitz S (1969) Inhibition of imiprarmine metabolism by methylphenidate [abstract]. Fed Proc 28:418.
69. Popper CW (1995) Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolescent Psychopharmacol 5:157-166.
70. Rettie AE, Korzekwa KR, Kunze KL, Lawrence AF, Eddy AC, Aoyama T et al. (1992) Hydroxylalion of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
71. Ririe DG, Ririe KL, Sethna NF, Fox L (1997) Unexpected interaction of methylphenidate (Ritalin) with anesthetic agents. Paediatr Anaesth 7:69-72.
72. Roberts SM Harbison RD Roth L James RC (1994) Methylphenidate induced hepatotoxicity in mice and its potentiation by β-adrenergic agonist drugs. Life Sci 55:269-281.
73. Rothman R (1995) Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a case series. J Subst Abuse Treat 12:449-453.
74. Sallee FR, Stiller RL, Perel JM, Bates T (1985) Oral pemoline kinetics in hyperactive children. Clin Pharmacol Therap 37:606-609.
75. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Ann Rev of Pharmacol Toxicol 32:639-677.
76. Sherrnan M, Hauser GC, Glover BH (1964) Toxic reactions to tranylcypromine. Am J Psychiatry 120:1019-1021.
77. Silverstone T, Fincham J, Wells B, Kyriadides M (1980) The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man. Neuropsychopharmacology 19:1235-1237.
78. Skejelbo E, Brosen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Therapeutics 49:18-23.
79. Spencer T, Biederman J, Wilens T, Harding M, O'Donnel D, Griffin S (1996) Pharmacotherapy of attention-deficit hyperactivity across the life cycle. J Am Acad Child Adolescent Psychiatry 35:409-432.
80. Starke K (1972) Interactions of guanethidinc and indirect-acting sympathomimetic amines. Arch Int Pharmacodyn Therap 195:309-314.
81. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO (1996) Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 57:72-76.
82. Swanson JM, Lerner M, Williams L (1995a) The more frequent diagnosis of attention deficit-hyperactivity disorder. New Engl J Med 333:944.
83. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L (1995b) Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolescent Psychopharmacology 5:301-304.
84. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB (1991) Neuronal cytochrome P450IId1 (Debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 40:63-68.
85. Vermeulen NPE, Teunissen MWE, Breimer DD (1979) Pharmacokinetics of pemoline in plasma, saliva, and urine following oral administration. Br J Pharmacol 8:459-463.
86. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochem Biophys Res Commun 175:1112-1118.
87. Wald D, Ebstein RP, Belmaker R (1978) Haloperidol and lithium blocking of the mood response to intravenous methylhenidate. Psychopharmacology 57:83-87.
88. Wender P (1986) Concurrent therapy with d-amphetamine and adrenergic drugs [letter]. Am J Psychiatry 143:259-260.
89. Wharton RN, Perel JM, Dayton PG, Malitz S (1971) A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 127:55-61.
90. Wilens TE, Spencer T, Biederman J, Wozniak F, Connor DF (1995) Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolescent Psychiatry 34: 110-112.
91. Zeck P (1961) The dangers of some antidepressant drugs [letter]. Med J Austr 2:607-608.
92. Zeidenberg P, Perel JM, Kanzler M, Wharton RN, Malitz S (1971) Clinical and metabolic studies with imipramine in man. Am J Psychiatry 127:57-62.